ProLiFiler – Cell Panel Screening
The ProLiFiler service is suitable for testing the therapeutic efficacy of test compounds on a panel of 140 human cancer cell lines using CellTiter-Glo readout.
Our cell panel screening service can answer numerous research questions:
- Which tumor cell lines are sensitive to your drug?
- Which cancer types are susceptible to treatment?
- What is the genomic signature of your drug for the prediction of anticancer drug response?
- Determine the sensitivity profile of your drug for computational comparison to hundreds of cancer drugs for confirmation of the mode of action via our MoA Finder tool.
Cell line panel screening provides efficacy data for 140 tumor cell lines from across 18 tumor types to identify the most responsive tumor entities and determine which cell lines are best suited for subsequent studies with more sophisticated 3D cell culture models or animal studies, all of which can be performed with Reaction Biology.
Advantages of Reaction Biology's ProLiFiler:
- Performed on a regular basis
- Huge cost-savings
- Fast turnaround time: get your results in only 6 weeks
- Semi-automated processing for highly reproducible data
- Single drug or combination drug testing
- Option for in-depth bioinformatics analysis
Cell Panel Screening Details
Cells were seeded in cell culture-treated 384 multi-well plates in the respective medium (A). After overnight incubation at 37 °C, compounds are dispensed by a Nanodrop Tecan D300e machine (B). Cells are treated for 72 h at 37°C at 5 % or 10% CO2 (C). Finally, cell plates are equilibrated to room temperature and the viability of cells is determined with CellTiter-Glo luminescent reagent based on the amount of ATP present (D).
The semi-automated screening process produces highly reproducible data. In every run a reference compound serves as the control reference compound. Shown here are the mean data and standard error of results from 4 independent ProLiFiler runs.
Setup: IC50 determination or single concentration testing with CellTiter-Glo readout. Drug combination testing is also an option, see an example study here.
Controls: DMSO only treatment serves as high control. Staurosporine treatment (at 1x10-5M) serves as the low control. In every project, the IC50 value determination of a reference compound is included.
Report: A detailed report including assay conditions, methodology, and comprehensive evaluation of data as well as raw data for each analysis will be provided.
Testing of subsets: For testing a subset of cell lines, or single concentration screening of multiple compounds, please see our Cell Proliferation Assay service with the free choice setup here.
Screening Facility: The ProLiFiler cell line panel screening is performed in Freiburg, Germany.
Compound requirements: In brief: 100 µl of the stock solution with 1000x the highest testing concentration or the equivalent as solid material.
Please find the screening schedule here. Results are available after 6 weeks.
Identification of cell lines sensitive to a MET kinase inhibitor. The MET inhibitor was tested for anti-proliferative and cytotoxic capacity with the ProLiFiler cell line panel. Three cell lines were most receptive to treatment including MKN-45, LOVO, and Karpas 299.
Identification of the tumor origin most sensitive to a MET kinase inhibitor. IC50 values of the inhibitor potency on a panel of tumor cell lines were sorted based on the tumor entity. Colon tumors (red) were most susceptible to treatment.
Our bioinformatics analysis tools are available to identify the mechanism of action of your test compound and to detect suitable biomarkers for stratification of responders vs. non-responders.
To offer these analytic tools, we have partnered with 4HF Biotec GmbH, a bioinformatics firm specializing in cancer data mining to discover new anti-cancer drugs. 4HF Biotec performs the data mining analysis based on their proprietary database and provides hands-on support with a high focus on client communication to answer your key questions.
Related Resources
